First regulatory approval for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) Represents an important n...
Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval ...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pac...
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including th...
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome&r...
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen ...
First partnership announced under Verge Labs' platform-first model; Tenacia will apply Verge's AI platform and proprietary multimodal...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
As drug development becomes increasingly complex, early-phase clinical trials are taking on a far more strategic role than simply establish...
Global pharmaceutical leader Lupin Limited announced that the United States Food and Drug Administration (U.S. FDA) has approved its ranibizum...
Mevion Medical Systems has signed a definitive purchase agreement to bring the MEVION S250-FIT Proton Therapy System™ to Tam Anh General Hospital i...
- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s - - CSP2026 is a growth strategy that will deliver profitab...
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). ...
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Innovent Biologics, Inc. ("I...
© 2026 Biopharma Boardroom. All Rights Reserved.
